Igc Pharma, INC 8-K filings

IGC Pharma, Inc. announced that its CEO and CFO purchased company stock by canceling significant outstanding debts owed to them by the company.

IGC Pharma, Inc. has amended its Master Loan and Security Agreement with O-Bank Co., Ltd., extending the facility with a $12 million aggregate limit and a revised fee structure.

IGC Pharma has entered into two securities purchase agreements to raise $514,960 in aggregate principal through convertible promissory notes.

IGC Pharma, Inc. completed a registered direct offering, issuing 779,997 common shares at $0.30 each, raising approximately $234,000 for working capital and clinical development.

IGC Pharma, Inc. announced a change in its fiscal year-end from March 31 to December 31, effective December 31, 2025.

IGC Pharma, Inc. has officially increased its authorized common stock from 150 million to 600 million shares, effective December 12, 2025, following stockholder approval.

IGC Pharma's subsidiary completed the sale of its Vancouver facility assets for $2.7 million in non-cash consideration, resulting in a $1.05 million gain.

IGC Pharma's stockholders approved the election of directors, auditor ratification, a 5 million share grant for incentives, and a significant increase in authorized common stock.

IGC Pharma's subsidiary, Holi Hemp LLC, sold its processing equipment, inventory, and facility to Wellness Essentials Northwest Inc. for approximately $2.7 million, securing preferential supply rights.

IGC Pharma, Inc. announced positive interim results from its Phase 2 CALMA trial for IGC-AD1, showing significant improvements in agitation and sleep disturbance in Alzheimer's patients with a favorable safety profile, outperforming a comparative industry standard.

IGC Pharma has entered into a share purchase agreement to sell 588,235 shares of common stock for $200,000 to Moran Global Strategies, a firm owned by a company director.

IGC Pharma's 2024 Annual Meeting of Stockholders saw the approval of all proposals, including the election of new directors and the grant of 5 million shares for employees and advisors.

IGC Pharma has extended its existing loan agreement with O-Bank, maintaining the same terms and conditions with a reduction in facility fees.

IGC Pharma's IGC-AD1 shows statistically significant reduction in agitation in Alzheimer's patients in an interim Phase 2 trial analysis.

IGC Pharma has entered into a share purchase agreement with Bradbury Asset Management for a $3 million private placement to support general corporate purposes and the advancement of its investigational medicines.

IGC Pharma has entered into a sales agreement with A.G.P./Alliance Global Partners to potentially sell up to $60 million of its common stock through an at-the-market offering.

IGC Pharma has appointed Terry Lierman, a seasoned healthcare leader, as an independent director to its board, aiming to leverage his expertise in advancing their Alzheimer's pipeline.